Explore

Rapid Read Rapid Read
Curebound Allocates $8.5 Million for Cancer Research, Including $1 Million Cure Prize

Curebound Allocates $8.5 Million for Cancer Research, Including $1 Million Cure Prize

Curebound, a philanthropic organization dedicated to cancer research, has announced the allocation of $8.5 million in grants to support 23 new cancer research studies. This funding includes a $1 million Cure Prize aimed at groundbreaking research with immediate clinical applications. The grants cover various research areas such as cancer risk detection, novel therapeutics, and personalized immunotherapy. Curebound's initiative is part of its broader mission to accelerate cancer research and improve treatment outcomes, having already funded $51.5 million in research grants to date.
Rapid Read Rapid Read
Diakonos Oncology Secures $7 Million Grant to Advance Melanoma Therapy

Diakonos Oncology Secures $7 Million Grant to Advance Melanoma Therapy

Diakonos Oncology Corp., a biotechnology company based in Houston, has been awarded a significant research grant exceeding $7 million by the Cancer Prevention and Research Institute of Texas (CPRIT). This funding will support the advancement of their innovative therapy, DOC1021, into a Phase 1/2 clinical trial targeting refractory melanoma. DOC1021 is a first-in-class, patient-derived dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The therapy aims to address the unmet medical needs of patients with refractory melanoma, a form of skin cancer that no longer responds to standard treatments like immune checkpoint inhibitors. The grant positions Diakonos as one of only nine awardees from a competitive pool of 164 applicants.
Rapid Read Rapid Read
Chronotherapy in Cancer Treatment: Timing Drug Delivery to Boost Survival Rates

Chronotherapy in Cancer Treatment: Timing Drug Delivery to Boost Survival Rates

Recent research suggests that timing the administration of cancer drugs according to patients' circadian rhythms could significantly improve treatment outcomes. Studies have shown that administering immunotherapy drugs in the morning, when immune T-cells are more active, can enhance their effectiveness. A study involving patients with non-small cell lung cancer (NSCLC) found that those receiving treatment before 11:30 am had nearly double the survival rate compared to those treated later in the day. This approach, known as chronotherapy, leverages the body's internal clock to optimize drug efficacy and minimize side effects.
Rapid Read Rapid Read
New Organ-on-a-Chip Technology Advances Cancer Vaccine Development for Aging Populations

New Organ-on-a-Chip Technology Advances Cancer Vaccine Development for Aging Populations

Researchers at the Terasaki Institute for Biomedical Innovation have developed a new organ-on-a-chip platform that models age-dependent immune responses. This technology allows for more accurate testing of cancer vaccine efficacy in older adults, who are most affected by cancer and often overlooked in traditional preclinical testing. The platform mimics the lymph node environment, capturing functional differences in immune responses between young and older lymphocytes. This advancement addresses the limitations of current 2D culture systems, which fail to replicate complex age-specific immune responses.
Rapid Read Rapid Read
Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Recent research has shown that fasting can enhance the efficacy of breast cancer therapies by activating glucocorticoids. The study, conducted on mice, found that fasting reduced levels of insulin, IGF1, and leptin, which are factors that can promote tumor growth. By lowering these factors, fasting improved the effectiveness of breast cancer treatments, leading to reduced tumor size. The research highlights the potential of dietary interventions as a complementary approach to traditional cancer therapies. The study was conducted in accordance with ethical guidelines and involved various experimental models to assess the impact of fasting on tumor growth and treatment efficacy.
Rapid Read Rapid Read
CytoAgents to Present New Data on CTO1681 at ESMO Immuno-Oncology Congress

CytoAgents to Present New Data on CTO1681 at ESMO Immuno-Oncology Congress

CytoAgents, Inc., a clinical-stage biotechnology company, is set to present new data on its investigational drug CTO1681 at the ESMO Immuno-Oncology Congress 2025. CTO1681 is an oral immunomodulator designed to reduce inflammation in the tumor microenvironment, particularly for patients undergoing CAR T-Cell Therapy. The data from two non-clinical studies show that CTO1681 can attenuate cytokines responsible for Cytokine Release Syndrome (CRS) without affecting the anti-tumor efficacy of CAR T-Cell Therapy. This development could lead to safer administration of CAR T-Cell Therapy, potentially allowing for outpatient treatment and broader patient access.
Rapid Read Rapid Read
BostonGene Unveils AI-Driven Breast Cancer Breakthroughs at SABCS 2025

BostonGene Unveils AI-Driven Breast Cancer Breakthroughs at SABCS 2025

BostonGene presented seven studies at the San Antonio Breast Cancer Symposium, showcasing its AI-driven platform's ability to uncover complex tumor biology and inform personalized treatment strategies. The research, conducted in collaboration with leading cancer centers, highlighted the platform's capability to identify predictive immune signatures, profile tumor microenvironments, and reveal novel therapeutic targets. These findings demonstrate the potential of BostonGene's technology to optimize breast cancer treatment and improve patient outcomes.
Rapid Read Rapid Read
Study Finds GLP-1 Drugs May Not Affect Risk of Obesity-Related Cancers

Study Finds GLP-1 Drugs May Not Affect Risk of Obesity-Related Cancers

A new study published in the Annals of Internal Medicine suggests that GLP-1 drugs, such as Ozempic and Zepbound, likely have little or no effect on the risk of developing 13 obesity-related cancers. The research analyzed data from 48 randomized controlled trials involving over 94,000 patients with Type 2 diabetes, overweight, or obesity. The study found that GLP-1 drugs did not significantly alter the risk of cancers such as breast, kidney, thyroid, and pancreatic, among others.
Rapid Read Rapid Read
USA Today Highlights Breast Health in Special Issue Focusing on Cancer Detection and Mental Health

USA Today Highlights Breast Health in Special Issue Focusing on Cancer Detection and Mental Health

USA Today has released a special issue dedicated to breast health, emphasizing the importance of cancer detection and treatment. The issue also explores the significant role that mental health plays in the journey of those affected by breast cancer. This comprehensive coverage aims to provide readers with valuable insights into the latest advancements in cancer detection technologies and treatment options. Additionally, the issue addresses the psychological impact of a cancer diagnosis and the importance of mental health support for patients and their families.
Trendline Trendline
New Organ-on-a-Chip Technology Advances Cancer Vaccine Development for Aging Populations

New Organ-on-a-Chip Technology Advances Cancer Vaccine Development for Aging Populations

New Organ-on-a-Chip Technology Advances Cancer Vaccine Development for Aging Populations
Rapid Read Rapid Read
BostonGene to Present AI-Driven Breast Cancer Research at SABCS 2025

BostonGene to Present AI-Driven Breast Cancer Research at SABCS 2025

BostonGene, a leader in AI-driven cancer research, is set to present seven studies at the San Antonio Breast Cancer Symposium (SABCS) 2025. These studies highlight the use of BostonGene's omnimodal profiling to identify predictive immune signatures and novel therapeutic targets for breast cancer treatment. The research, conducted in collaboration with leading cancer centers, aims to enhance personalized treatment strategies by uncovering complex tumor biology. Key presentations include the use of BostonGene's platform to profile immune responses in triple-negative breast cancer and the identification of new druggable targets in inflammatory breast cancer. The studies demonstrate the potential of AI to improve patient stratification and optimize therapy in breast cancer treatment.
Rapid Read Rapid Read
CRISPR Gene Editing Shows Promise in Reversing Incurable Leukemia

CRISPR Gene Editing Shows Promise in Reversing Incurable Leukemia

A groundbreaking therapy using CRISPR gene editing has shown success in reversing aggressive and previously incurable blood cancers in some patients. The treatment involves editing the DNA in white blood cells to transform them into a cancer-fighting 'living drug.' This innovative approach has been applied to patients with T-cell acute lymphoblastic leukemia, a condition where T-cells grow uncontrollably. The therapy, which was once considered science fiction, has led to remission in nearly two-thirds of the treated patients. The process involves multiple genetic modifications to T-cells, enabling them to target and destroy cancerous cells without harming healthy ones. The study, conducted by University College London and Great Ormond Street Hospital, has been published in the New England Journal of Medicine.